高危继发中枢神经系统受累的弥漫性大B细胞淋巴瘤:静脉大剂量甲氨蝶呤中枢预防无效及基线脑脊液分析的重要性
本研究回顾性分析连续诊断的高危系统性弥漫性大B细胞淋巴瘤患者,基线脑脊液分析排除无症状软脑膜受累后,比较接受与未接受单途径大剂量甲氨蝶呤中枢预防的5年中枢复发率及生存结局。结果显示预防组与未预防组5年中枢复发率无显著差异(6.2% vs 5.6%),调整HR 1.08(95%CI 0.41-2.85),p=.88。基线脑脊液软脑膜受累患者中枢复发/进展风险显著增高(HR 10.7,95%CI 5.35-21.37,p<.0001),无进展生存和总生存更差。
要点
- 大剂量甲氨蝶呤中枢预防未降低高危系统性弥漫性大B细胞淋巴瘤患者的中枢复发风险。
- 基线脑脊液分析排除软脑膜受累后,预防组与未预防组5年中枢复发率分别为6.2%和5.6%,无显著差异。
- 基线脑脊液软脑膜受累患者中枢复发/进展风险显著增高,HR 10.7(95%CI 5.35-21.37),p<.0001。
核心结论
- 对于基线脑脊液分析排除了软脑膜受累的高危系统性弥漫性大B细胞淋巴瘤患者,大剂量甲氨蝶呤中枢预防不降低中枢复发风险。
- 基线脑脊液检查存在同步软脑膜受累的无症状患者,与无脑脊液受累患者相比,后续中枢疾病事件风险增加且生存更差。
研究设计与样本
- 回顾性识别连续诊断的高危系统性弥漫性大B细胞淋巴瘤患者,基线脑脊液分析排除软脑膜受累(noCNS组),按是否接受大剂量甲氨蝶呤中枢预防分层。
- 比较noCNS组中接受与未接受预防患者的5年中枢复发率及生存结局;并将诊断时脑脊液分析显示同步软脑膜受累(CNSinv组)患者的生存结局与noCNS组进行二次分析。
主要发现
- 大剂量甲氨蝶呤预防组与未预防组5年中枢复发率分别为6.2%和5.6%,调整HR 1.08(95%CI 0.41-2.85),p=.88,无显著差异(总n=445)。
- 预防组与未预防组5年无进展生存和总生存风险均无显著差异。
- CNSinv患者中93.3%有至少1个结外部位。
- CNSinv组与全部noCNS组相比,中枢复发/进展风险增高(5年风险;HR 10.7 [95%CI 5.35-21.37],p<.0001),无进展生存和总生存更差。
- CNSinv组总生存优于后来发生中枢复发的noCNS组(HR 0.55,p=.052)。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High-dose intravenous methotrexate (HD-MTX) CNS prophylaxis in high-risk diffuse large B cell lymphoma (DLBCL) remains controversial. We describe real-world CNS relapse incidence following baseline cerebrospinal fluid (CSF) analysis to exclude asymptomatic leptomeningeal involvement in newly diagnosed high-risk DLBCL patients with versus without single-route HD-MTX CNS prophylaxis. Consecutively diagnosed high-risk systemic DLBCL patients without leptomeningeal involvement by CSF analysis (noCNS) were identified retrospectively. Five-year CNS relapse incidence and survival outcomes were examined, as stratified by receipt of HD-MTX prophylaxis. Secondary analysis of survival outcomes in patients with synchronous leptomeningeal involvement (CNSinv) by CSF analysis at diagnosis were compared with the noCNS group. No significant difference in 5-year CNS relapse incidence was observed following HD-MTX prophylaxis versus no prophylaxis (total n = 445) despite similar CNS-IPI risk; 6.2% versus 5.6%, adjusted HR 1.08 (95% CI 0.41-2.85), p = .88; nor in 5-year progression free survival (PFS) or overall survival (OS) risk. Of CNSinv patients, 93.3% had ≥1 extranodal site. Increased CNS relapse/progression risk (5-year risk; HR 10.7 [95% CI 5.35-21.37], p < .0001) and inferior PFS and OS were observed in CNSinv versus all noCNS patients. The CNSinv group had superior OS compared with noCNS patients who later experienced CNS relapse (HR 0.55, p = .052). HD-MTX prophylaxis does not reduce CNS relapse risk in high-risk systemic DLBCL without leptomeningeal involvement by CSF analysis at diagnosis. Asymptomatic patients with synchronous leptomeningeal involvement on baseline CSF examination are at increased risk of further CNS disease events and inferior survival compared to patients without CSF involvement.
引用
- Bennett R, Ruskova A, Coomarasamy C, et al. Diffuse large B-cell lymphoma at risk of secondary CNS involvement: The inefficacy of intravenous high-dose methotrexate CNS prophylaxis and the importance of baseline cerebrospinal fluid analysis. Am J Hematol. 2023. PMID: 37161765. doi:10.1002/ajh.26953
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。